GGrantIndex
← Search

PA-21-259, SBIR, Phase I, Self-Amplifying RNA Replicon-Based Platform for Generating Multivalent Influenza Vaccine

$263,991R43FY2022IPCDC

Carogen Corporation, Hamden CT

Investigators

Valerian Nakaarcontact
View original record on NIH RePORTER →
PA-21-259, SBIR, Phase I, Self-Amplifying RNA Replicon-Based Platform for Generating Multivalent Influenza Vaccine · GrantIndex